CNS patents
This article was originally published in The Tan Sheet
Executive Summary
The U.S. Patent & Trademark Office will reexamine two of CNS' nasal strip patents, the Minneapolis-based Breathe Right manufacturer says Nov. 24. The review comes at the behest of Silver Eagle Labs, a defendant in a patent infringement case filed by CNS earlier this year; Silver Eagle counterclaimed that the patents are invalid. CNS CEO Marti Morfitt says the firm is "confident of the strength of our patents and we will continue to aggressively defend them." CNS is planning to ship two Breathe Right line extensions in early 2005 ("1The Tan Sheet" Nov. 22, 2004, In Brief)...
You may also be interested in...
Fiber candy
Tropical orange-flavored low-sugar Fiber Drops will begin shipping in March and reach shelves in April, CNS announces. Two pieces of the hard candy FiberChoice line extension provides 4 g fiber. No-sugar and no-carb FiberChoice chewable tablets, also with 4 g fiber each, will be shipped with the drops. A 72-count box of individually wrapped Fiber Drops and a 90-count bottle of Assorted Fruit Flavor chews share an SRP of $9.99 to $12.99. The Minneapolis-based firm will discuss two Breathe Right extensions for its next fiscal year in early 2005...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.